Gregory Stein, M.D., M.B.A.
Chief Executive Officer
Dr. Stein co-founded Curtana Pharmaceuticals and became the company’s Chief Executive Officer in April, 2013. During his professional career of over 20 years, he has been a clinician and a life sciences executive with experience in the areas of diagnostics, medical devices, pharmaceuticals and biotechnology.
Prior to co-founding Curtana, Dr. Stein served as the Vice President, Operations and Medical Affairs at Sova Pharmaceuticals, Inc., a venture-backed company he co-founded in March, 2010. The company is focused on the development of novel therapeutic drugs for the treatment of inflammatory and neuropathic pain. Prior to Sova, he was the Senior Director of Product Marketing at Genoptix, which was recently acquired by Novartis. Genoptix is a specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to community-based hematologists and oncologists. Prior to joining Genoptix, Dr. Stein was an entrepreneur with a focus on identifying innovative technology for commercial development in the medical therapeutic, device and diagnostic areas. He has been the founder of two other early-stage drug development companies, Opus Pharmaceuticals and Uzima Bioscience.
Before pursuing a career in the business world, Dr. Stein practiced Emergency Medicine in a busy urban hospital on the west side of Chicago where he served as the Assistant Medical Director of the department and Associate Emergency Medical Services Director for the regional EMS system.
Dr. Stein is board certified in Emergency Medicine. He completed his residency at the University of Illinois Affiliated Hospitals in Chicago and is a graduate of the 3-year accelerated Independent Study Program at the Ohio State University School of Medicine. Dr. Stein received a B.A. in Psychology from UC San Diego and an M.B.A. from The Rady School of Management at UC San Diego.
Graham Beaton, Ph.D.
Vice President of Medicinal Chemistry and Drug Discovery
Dr. Graham Beaton serves as VP, Medicinal Chemistry and Drug Discovery at Curtana Pharmaceuticals. He has the expertise, leadership and motivation necessary to successfully carry out the mission required for a start-up pharmaceutical company. Dr. Beaton has over 22 years of experience in industrial science, the past 14 years of which have been in the successful management of research teams. He brings significant experience in all aspects of drug discovery, including medicinal chemistry, program management and organic synthesis.
Prior to this at Neurocrine Biosciences, Dr. Beaton led research teams that identified multiple development candidates in H1-antihistamine and GnRH antagonist programs. The antihistamine program completed selection of the clinical candidate and the identification of a backup using a novel Phase 0 strategy. Following this, Dr. Beaton managed the discovery and pre-clinical selection of a series of novel small-molecule GnRH antagonists as backup to the current clinical compound Elagolix. These compounds remain undisclosed except in the patent literature and remain an integral part of the collaboration Neurocrine currently holds with Abbott Laboratories. Prior to joining Neurocrine, he was at CombiChem Inc. and DuPont pharmaceuticals, where he managed discovery efforts leading to the identification of lead molecules for pre-clinical proof of concept in 3 programs in cardiovascular, metabolic and oncology disease areas. Prior to joining CombiChem, Dr. Beaton was a Research Scientist at Amgen.
Dr. Beaton did his postdoctoral work in chemistry and biochemistry at the University of Colorado at Boulder. He received a Ph.D. in Chemistry from The University of Birmingham in the UK. He has authored or co-authored over 30 peer-reviewed publications and is an inventor on 10 patents and patent applications. Dr. Beaton participates in several National Institutes of Health grant review panels to evaluate novel, early-stage compounds as viable therapeutics for IND filing.
Gordon Alton, Ph.D.
Vice President of Research and Development
Dr. Gordon Alton currently serves as Vice President of Research and Development at Curtana Pharmaceuticals. He has more than 19 years of structure-based drug discovery experience in oncology, inflammation, metabolic disease, CNS diseases and ophthalmology. He has deep knowledge of signal transduction, kinases, nuclear receptors, GPCRs, phosphodiesterases and metabolic enzymes. He has importantly contributed to the successful development of multiple drugs, clinical candidates and INDs. These include the T-cell activator Revlimid® for multiple myeloma and Xalkori® for anaplastic large cell lymphoma and non-small cell lung carcinoma. Prior to his role at Curtana, he was the President and CEO of Visionary Pharmaceuticals, which is an early-stage drug discovery company focused on inflammation and oncology.
Previously, he was the founder and chief consultant at Altonyx Consulting providing due diligence on compound in-licensing and drug discovery out-sourcing to biotechnology companies. From 2001-2009, he worked at Pfizer Global R&D where he led multiple drug discovery projects and was a member of the Oncology Strategic Alliance Advisory Group. He also managed several academic collaborations at Scripps and Case Western Reserve University and served on corporate business development teams.
Dr. Alton completed his postdoctoral fellowship at The Burnham Institute in La Jolla, CA. He holds a B.Sc. in Chemistry/Physics and a Ph.D. in Biochemistry from the University of Alberta in Canada. He has authored or co-authored 35 peer-reviewed publications.